The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
Open accessAbstract
BACKGROUND: The development of radiopharmaceuticals containing 225Ac for targeted alpha therapy is an active area of academic and commercial research worldwide. OBJECTIVES: Despite promising results from recent clinical trials, 225Ac-radiopharmaceutical development still faces significant challenges that must be overcome to realize the widespread clinical use of 225Ac. Some of these challenges include the limited availability of the isotope, the challenging chemistry required to isolate 225Ac from any co-produced isotopes, and the need for stable targeting systems with high radiolabeling yields. RESULTS: Here we provide a review of available literature pertaining to these challenges in the 225Acradiopharmaceutical field and also provide insight into how performed and planned efforts at TRIUMF - Canada's particle accelerator centre - aim to address these issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These radiolabelled compounds, now armed with radioactive ability, allow doctors and researchers to see, measure, and adjust what is happening in the body at the molecular level [10].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Further in vitro serum stability testing showed that the 225Ac-DOTA complex outperformed the rest with >90% of complexes still intact after 10 days (104).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,187
Matching chelators to radiometals for radiopharmaceuticals
Price, E. W., & Orvig, C. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60304k · Cited by 1,064
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Tumor therapy with targeted atomic nanogenerators.
McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science · doi:10.1126/science.1064126 · Cited by 501
Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R. A., Murphy, K., Haberkorn, U., & Morgenstern, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2857-9 · Cited by 418
Radioimmunotherapy with alpha-emitting nuclides
McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Jurcic, J. G., Larson, S. M., & Scheinberg, D. A. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050306 · Cited by 403
An overview of targeted alpha therapy
Kim, Y., & Brechbiel, M. W. (2011) · Tumor Biology · doi:10.1007/s13277-011-0286-y · Cited by 280
Tumour targeting with radiometals for diagnosis and therapy
Ramogida, C. F., & Orvig, C. (2013) · Chemical Communications · doi:10.1039/c3cc41554f · Cited by 268
Self-citationA Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters?
de Kruijff, R. M., Wolterbeek, H. T., & Denkova, A. G. (2015) · Pharmaceuticals · doi:10.3390/ph8020321 · Cited by 254
Design and synthesis of 225Ac radioimmunopharmaceuticals.
McDevitt, M. R., Ma, D., Simon, J., Frank, R. K., & Scheinberg, D. A. (2002) · Applied Radiation and Isotopes · doi:10.1016/s0969-8043(02)00167-7 · Cited by 225
Research works printed but not linked: 5
- [26]Dilling J. Kreuken R. Merminga L. ISAC and ARIEL: The TRIUMF Radioactive Beam Facilities and the Scientific Program. Springer 2014
- [35]Stacey M.W. Nuclear Reactor Physics. 2nd ed Weinheim, Germany Wiley-VCH 2007
- [41]Lesrel J. Arianer J. Arianer M. Bajeat O. Buhour J-m. Byzl H. Carrey F. Chabot M. Corbin T. Croizet H. Curaudeau J. Doizon F. Ducourtieu M. Dufour J-m. Grialou D. Joly C. Kaminski M. Lefort H. Lesellier B. Magneney G. Mottet L. Planat C. Raynaud M. Richard Y. Said A. Semsoum A. Taquin F. Vogel C. Bienvenu G. Cayla J-n. Lal M.D. Commissioning of the Alto 50 MeV Electron Linac. Proc. EPAC 2006 2006 3 5
- [47]Jost C.U. Griswold J.R. Bruffey S.H. Mirzadeh S. Stracener D.W. Williams C.L. Measurement of cross sections for the 232Th(P,4n) 229Pa reaction at low proton energies. AIP Conf. Proc. 2013 1525 520 524
- [71]Merminga L. Ames F. Baartman R. Bricault P. Bylinski Y. Chao Y.C. Dawson R. Kaltchev D. Koscielniak S. Laxdal R. Mammarella F. Marchetto M. Minor G. Mitra A. Rao Y.N. Trinczek M. Trudel A. Verzilov V. Zvyagintsev V. ariel: triumf’s advanced rare isotope laboratory. Proceedings of 2011 IPAC2011 1917 1919
Cited by
Sorted by citations
Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations
Filosofov, D. V., Kurakina, E. S., & Radchenko, V. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.12.001 · Cited by 342
Self-citationTerbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
Müller, C., Umbricht, C. A., Gracheva, N., Tschan, V. J., Pellegrini, G., Bernhardt, P., Zeevaart, J. R., Köster, U., Schibli, R., & van der Meulen, N. P. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04345-0 · Cited by 243
Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”
Eychenne, R., Chérel, M., Haddad, F., Guérard, F., & Gestin, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060906 · Cited by 210
Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications.
Nelson, B. J. B., Andersson, J. D., & Wuest, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010049 · Cited by 194
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144
“These radi-olabelled compounds, now armed with radioactive ability, allow doctors and researchers to see, measure, and adjust what is happening in the body at the molecular level [10].”
Background
Metadata
- Authors
- Robertson, A. K. H., Ramogida, C. F., Schaffer, P., & Radchenko, V.
- Affiliations
- TRIUMF (CA)
- Corresponding author
- Radchenko, Valery
- Venue
- Current Radiopharmaceuticals
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2018-10-22
- Volume
- 11
- Issue
- 3
- Pages
- 156-172
- ISSN
- 1874-4710 (ISSN-L)
- PMC
- PMC6249690
- OpenAlex
- W2801430183
- Cited by
- 202
- References
- 59
- Citations by year
- 2026: 23 · 2025: 35 · 2024: 34 · 2023: 24 · 2022: 22 · 2021: 29 · 2020: 26 · 2019: 8 · 2018: 1
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- Locations
- Current Radiopharmaceuticals (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Chemical Reactions and Isotopes
- Physical Sciences › Physics and Astronomy › Radiation › Radioactivity and Radon Measurements
- Keywords
- actinium-225, radiopharmaceuticals, targeted alpha therapy, TRIUMF, isotope separation, radiolabeling yield, alpha-emitting radionuclides
- MeSH terms
- Actinium, Alpha Particles, Humans, Neoplasms, Radiochemistry, Radionuclide Generators, Radiopharmaceuticals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
